Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and Imidazoquinolines
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Endosomal TLRs play an important role in innate immune response as well as in autoimmune processes. In the therapy of systemic lupus erythematosus, antimalarial drugs chloroquine, hydroxychloroquine, and quinacrine have been used for a long time. Their suppression of endosomal TLR activation has been attributed to the inhibition of endosomal acidification, which is a prerequisite for the activation of these receptors. We discovered that chloroquine inhibits only activation of endosomal TLRs by nucleic acids, whereas it augments activation of TLR8 by a small synthetic compound, R848. We detected direct binding of antimalarials to nucleic acids by spectroscopic experiments and determined their cellular colocalization. Further analysis revealed that other nucleic acid-binding compounds, such as propidium iodide, also inhibited activation of endosomal TLRs and colocalized with nucleic acids to endosomes. We found that imidazoquinolines, which are TLR7/8 agonists, inhibit TLR9 and TLR3 even in the absence of TLR7 or TLR8, and their mechanism of inhibition is similar to the antimalarials. In contrast to bafilomycin, none of the tested antimalarials and imidazoquinolines inhibited endosomal proteolysis or increased the endosomal pH, confirming that inhibition of pH acidification is not the underlying cause of inhibition. We conclude that the direct binding of inhibitors to nucleic acids mask their TLR-binding epitope and may explain the efficiency of those compounds in the treatment…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In phagocytic cells, the deacidification of endosomes using pharmacological inhibitors like chloroquine has been shown to reduce endosomal toll-like receptor (TLR) response (de Bouteiller et al., 2005; Fox, 2019; Kuznik et al., 2011; Wozniacka et al., 2006; Yang et al., 2016)”
From NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load (2021) · cites this paper as Kuznik et al., 2011
In the citing paper
“Hydroxychloroquine (HCQ) is an approved anti-malaria drug, and accumulation of hydroxychloroquine inhibits the binding ability of TLR9 to DNA and subsequent immune activation (77).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [77]
Citations
Cites
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
ACIDIFICATION OF THE ENDOCYTIC AND EXOCYTIC PATHWAYS
Mellman, I., Fuchs, R., & Helenius, A. (1986) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.55.070186.003311 · Cited by 2,032
Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors
Leadbetter, E. A., Rifkin, I. R., Hohlbaum, A. M., Beaudette, B. C., Shlomchik, M. J., & Marshak-Rothstein, A. (2002) · Nature · doi:10.1038/416603a · Cited by 1,900
Yoshimori, T., Yamamoto, A., Moriyama, Y., Futai, M., & Tashiro, Y. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)47429-2 · Cited by 1,328
Toll-like receptors in systemic autoimmune disease
Marshak-Rothstein, A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1957 · Cited by 1,116
Barrat, F. J., Meeker, T., Gregorio, J., Chan, J. H., Uematsu, S., Akira, S., Chang, B., Duramad, O., & Coffman, R. L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050914 · Cited by 928
Human lupus autoantibody–DNA complexes activate DCs through cooperation of CD32 and TLR9
Means, T. K., Latz, E., Hayashi, F., Murali, M. R., Golenbock, D. T., & Luster, A. D. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523025 · Cited by 849
Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8
Gorden, K. B., Gorski, K. S., Gibson, S. J., Kedl, R. M., Kieper, W. C., Qiu, X., Tomai, M. A., Alkan, S. S., & Vasilakos, J. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1259 · Cited by 683
Häcker, H., Mischak, H., Miethke, T., Liptay, S., Schmid, R., Sparwasser, T., Heeg, K., Lipford, G. B., & Wagner, H. (1998) · The EMBO Journal · doi:10.1093/emboj/17.21.6230 · Cited by 653
The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor
Ewald, S. E., Lee, B. L., Lau, L., Wickliffe, K. E., Shi, G.-P., Chapman, H. A., & Barton, G. M. (2008) · Nature · doi:10.1038/nature07405 · Cited by 617
Research works printed but not linked: 2
- Ahmad-Nejad, 2002, Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments, Eur. J. Immunol., 32, 1958, 10.1002/1521-4141(200207)32:7<1958::aid-immu1958>3.0.co;2-u · DOI · Paper page
- Peacocke, 1973, Acridines, 723
Cited by
Items 101–200 of 627
Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies
Allen, M. E., Rus, V., & Szeto, G. L. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.009 · Cited by 102
The Fatal Circle of NETs and NET-Associated DAMPs Contributing to Organ Dysfunction
Block, H., Rossaint, J., & Zarbock, A. (2022) · Cells · doi:10.3390/cells11121919 · Cited by 97
Recent progress in the development of Toll-like receptor (TLR) antagonists
Patra, M. C., & Choi, S. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1185415 · Cited by 94
Nucleic Acid Sensors as Therapeutic Targets for Human Disease
McWhirter, S. M., & Jefferies, C. A. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.004 · Cited by 91
Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation
Lai, C.-Y., Su, Y.-W., Lin, K.-I., Hsu, L.-C., & Chuang, T.-H. (2017) · Journal of Immunology Research · doi:10.1155/2017/7807313 · Cited by 88
Innate immunity and interferons in the pathogenesis of Sjögren’s syndrome
Bodewes, I. L. A., Björk, A., Versnel, M. A., & Wahren‐Herlenius, M. (2018) · Rheumatology · doi:10.1093/rheumatology/key360 · Cited by 98
Torigoe, M., Sakata, K., Ishii, A., Iwata, S., Nakayamada, S., & Tanaka, Y. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.07.003 · Cited by 90
Albert, C. R., Schlesinger, W. J., Viall, C. A., Mulla, M. J., Brosens, J. J., Chamley, L., & Abrahams, V. M. (2013) · American Journal of Reproductive Immunology · doi:10.1111/aji.12184 · Cited by 90
The role of cytokines in the pathogenesis of cutaneous lupus erythematosus
Robinson, E. S., & Werth, V. P. (2015) · Cytokine · doi:10.1016/j.cyto.2015.01.031 · Cited by 86
Scavenging nucleic acid debris to combat autoimmunity and infectious disease
Holl, E. K., Shumansky, K. L., Borst, L. B., Burnette, A. D., Sample, C. J., Ramsburg, E. A., & Sullenger, B. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607011113 · Cited by 90
Julian, M. W., Shao, G., VanGundy, Z. C., Papenfuss, T. L., & Crouser, E. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072354 · Cited by 85
Prevention and treatment of COVID‐19 disease by controlled modulation of innate immunity
Schijns, V. E. C. J., & Lavelle, E. C. (2020) · European Journal of Immunology · doi:10.1002/eji.202048693 · Cited by 86
Floris, A., Piga, M., Mangoni, A. A., Bortoluzzi, A., Erre, G. L., & Cauli, A. (2018) · Mediators of Inflammation · doi:10.1155/2018/3424136 · Cited by 90
Cheng, L., Kiewiet, M. B. G., Groeneveld, A., Nauta, A., & de Vos, P. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.05.023 · Cited by 86
Halcrow, P. W., Geiger, J. D., & Chen, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.627639 · Cited by 89
The host targeting effect of chloroquine in malaria
Coban, C. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.07.005 · Cited by 87
Monogenic lupus: it's all new!
Costa‐Reis, P., & Sullivan, K. E. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.10.008 · Cited by 87
Farina, A., Peruzzi, G., Lacconi, V., Lenna, S., Quarta, S., Rosato, E., Vestri, A. R., York, M. R., Dreyfus, D. H., Faggioni, A., et al. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1237-9 · Cited by 85
Bodewes, I. L. A., Gottenberg, J., van Helden-Meeuwsen, C. G., Mariette, X., & Versnel, M. A. (2019) · Rheumatology · doi:10.1093/rheumatology/kez242 · Cited by 80
Eloranta, M., Alm, G. V., & Rönnblom, L. (2012) · Arthritis & Rheumatism · doi:10.1002/art.37821 · Cited by 79
MicroRNA-29b Modulates Innate and Antigen-Specific Immune Responses in Mouse Models of Autoimmunity
Salama, A., Fichou, N., Allard, M., Dubreil, L., de Beaurepaire, L., Viel, A., Jégou, D., Bösch, S., & Bach, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106153 · Cited by 77
Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade
Chuang, Y.-C., Tseng, J., Huang, L.-R., Huang, C., Huang, C. F., & Chuang, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01075 · Cited by 79
TLR9 and COVID-19: A Multidisciplinary Theory of a Multifaceted Therapeutic Target
Bezemer, G. F. G., & Garssen, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.601685 · Cited by 77
Impaired TLR9 responses in B cells from patients with systemic lupus erythematosus
Gies, V., Schickel, J., Jung, S., Joublin-Delavat, A., Glauzy, S., Knapp, A., Soley, A., Poindron, V., Guffroy, A., Choi, J.-Y., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96795 · Cited by 77
Roberts, J., Smylie, M., Walker, J. W. T., Basappa, N. S., Chu, Q. S.-C., Kolinsky, M. P., Lyddell, C., & Ye, C. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04451-2 · Cited by 75
Yoon, C. H., Lee, H. J., Lee, E. Y., Lee, E. B., Lee, W., Kim, M. K., & Wee, W. R. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.7.1127 · Cited by 72
Ganguly, D. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.07.001 · Cited by 72
Toll-Like Receptor (TLR)-7 and -8 Modulatory Activities of Dimeric Imidazoquinolines
Shukla, N. M., Mutz, C. A., Malladi, S. S., Warshakoon, H. J., Balakrishna, R., & David, S. A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2010207 · Cited by 75
Screening of herbal extracts for TLR2- and TLR4-dependent anti-inflammatory effects
Schink, A., Neumann, J., Leifke, A. L., Ziegler, K., Fröhlich‐Nowoisky, J., Cremer, C. G., Thines, E., Weber, B., Pöschl, U., Schuppan, D., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203907 · Cited by 71
Kandimalla, E. R., Bhagat, L., Wang, D., Yu, D., Sullivan, T., La Monica, N., & Agrawal, S. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt078 · Cited by 68
Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine
Bonam, S. R., Muller, S., Bayry, J., & Klionsky, D. J. (2020) · Autophagy · doi:10.1080/15548627.2020.1779467 · Cited by 68
Chighizola, C. B., Ubiali, T., & Meroni, P. L. (2015) · Journal of Immunology Research · doi:10.1155/2015/951424 · Cited by 67
Chernyavskaya, Y., Mudbhary, R., Zhang, C., Tokarz, D. A., Jacob, V., Gopinath, S., Sun, X., Wang, S., Magnani, E., Madakashira, B. P., et al. (2017) · Development · doi:10.1242/dev.147629 · Cited by 71
Brauner, S., Folkersen, L., Kvarnström, M., Meisgen, S., Petersen, S. H., Franzén-Malmros, M., Mofors, J., Brokstad, K. A., Klareskog, L., Jonsson, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210509 · Cited by 67
Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage
MOREUIL, C. D., Alavi, Z., & Pasquier, É. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14131 · Cited by 71
Delineating the deranged immune system in the antiphospholipid syndrome
van den Hoogen, L. L., van Roon, J. A. G., Radstake, T. R. D. J., Fritsch-Stork, R. D. E., & Derksen, R. H. W. M. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.08.011 · Cited by 66
Immunological drivers of IgA nephropathy: Exploring the mucosa–kidney link
Selvaskandan, H., Barratt, J., & Cheung, C. K. (2022) · International Journal of Immunogenetics · doi:10.1111/iji.12561 · Cited by 65
HU, J. L., Wang, X., Chen, X., Fang, Y., Chen, K., Peng, W., Wang, Z., Guo, K., Tan, X., Liang, F., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02430-0 · Cited by 65
Metabolic regulation of organelle homeostasis in lupus T cells
Caza, T. N., Talabér, G., & Perl, A. (2012) · Clinical Immunology · doi:10.1016/j.clim.2012.07.001 · Cited by 66
Karlsen, T. A., & Brinchmann, J. E. (2013) · Molecular Therapy · doi:10.1038/mt.2013.55 · Cited by 70
On Neutrophil Extracellular Trap (NET) Removal: What We Know Thus Far and Why So Little
Santocki, M., & Kołaczkowska, E. (2020) · Cells · doi:10.3390/cells9092079 · Cited by 64
Interplay of Infections, Autoimmunity, and Immunosuppression in Systemic Lupus Erythematosus
Caza, T. N., Oaks, Z., & Perl, A. (2014) · International Reviews of Immunology · doi:10.3109/08830185.2013.863305 · Cited by 67
Young, N. A., Valiente, G. R., Hampton, J. M., Wu, L., Burd, C. J., Willis, W. L., Bruss, M., Steigelman, H., Gotsatsenko, M., Amici, S. A., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.12.005 · Cited by 63
Zhu, F., Jiang, W., Bhagat, L., Wang, D., Yu, D. S., Tang, J. X., Kandimalla, E. R., Monica, N. L., & Agrawal, S. (2013) · Autoimmunity · doi:10.3109/08916934.2013.798651 · Cited by 64
Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease
Mullen, L., Chamberlain, G., & Sacre, S. M. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0645-y · Cited by 65
Pharmacological regulators of autophagy and their link with modulators of lupus disease
Gros, F., & Muller, S. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12792 · Cited by 63
Toll-like receptors in mediating pathogenesis in systemic sclerosis
Frasca, L., & Lande, R. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13426 · Cited by 60
Wolstencroft, P. W., Casciola-Rosen, L. A., & Fiorentino, D. F. (2018) · JAMA Dermatology · doi:10.1001/jamadermatol.2018.2549 · Cited by 58
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
Li, J., Wang, Y., Wang, X., Ye, L., Zhou, Y., Persidsky, Y., & Ho, W. (2013) · Blood · doi:10.1182/blood-2012-08-450353 · Cited by 52
Type I IFN signature in primary Sjögren’s syndrome patients
Brkić, Z., & Versnel, M. A. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.876364 · Cited by 64
Rose, T., Szelinski, F., Lisney, A., Reiter, K., Fleischer, S. J., Burmester, G. R., Radbruch, A., Hiepe, F., Grützkau, A., Biesen, R., et al. (2016) · RMD Open · doi:10.1136/rmdopen-2016-000292 · Cited by 57
Dysregulated IL-1β-GM-CSF Axis in Acute Rheumatic Fever That Is Limited by Hydroxychloroquine
Kim, M. L., Martin, W. J., Minigo, G., Keeble, J., Garnham, A. L., Pacini, G., Smyth, G. K., Speed, T. P., Carapetis, J. R., & Wicks, I. P. (2018) · Circulation · doi:10.1161/circulationaha.118.033891 · Cited by 59
Novel Treatment Paradigms: Primary IgA Nephropathy
Selvaskandan, H., Barratt, J., & Cheung, C. K. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.11.026 · Cited by 59
Saleki, K., Alijanizadeh, P., Javanmehr, N., & Rezaei, N. (2024) · Medicinal Research Reviews · doi:10.1002/med.22012 · Cited by 58
Emerging roles of Toll-like receptor 9 in cardiometabolic disorders
Nishimoto, S., Fukuda, D., & Sata, M. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00118-7 · Cited by 57
Application of chloroquine as an endosomal escape enhancing agent: new frontiers for an old drug
Hajimolaali, M., Mohammadian, H., Torabi, A., Shirini, A., Shal, M. K., Nezhad, H. B., Iranpour, S., Eftekhari, R. B., & Dorkoosh, F. A. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1873272 · Cited by 57
Association between systemic lupus erythematosus and disruption of gut microbiota: a meta-analysis
Xiang, S., Qu, Y., Qian, S., Wang, R., Wang, Y., Jin, Y., Li, J., & Ding, X. (2022) · Lupus Science & Medicine · doi:10.1136/lupus-2021-000599 · Cited by 60
TLR3 Agonist Poly-IC Induces IL-33 and Promotes Myelin Repair
Natarajan, C., Yao, S., & Sriram, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152163 · Cited by 58
Jimenez, A. L., Mowrey, W. B., Putterman, C., Buyon, J. P., Goilav, B., & Broder, A. R. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40575 · Cited by 55
Pokroy‐Shapira, E., Gelernter, I., & Molad, Y. (2014) · Clinical Rheumatology · doi:10.1007/s10067-014-2527-0 · Cited by 56
Anti-inflammatory medications for the treatment of mental disorders: A scoping review
Fitton, R., Sweetman, J., Heseltine-Carp, W., & van der Feltz-Cornelis, C. (2022) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2022.100518 · Cited by 53
Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons
Rother, N., Yanginlar, C., Lindeboom, R. G. H., Bekkering, S., van Leent, M. M. T., Buijsers, B., Jonkman, I., de Graaf, M. J. J., Baltissen, M. P. A., Lamers, L. A., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100146 · Cited by 60
LL-37 Peptide Enhancement of Signal Transduction by Toll-like Receptor 3 Is Regulated by pH
Singh, D., Vaughan, R. C., & Kao, C. C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.582973 · Cited by 55
Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics
Kandimalla, R. J. L., John, A. A., Abburi, C., Vallamkondu, J., & Reddy, P. H. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02022-0 · Cited by 53
Khan, N., Chen, X., & Geiger, J. D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595888 · Cited by 54
Short single-stranded DNA degradation products augment the activation of Toll-like receptor 9
Pohar, J., Lainšček, D., Ivičak‐Kocjan, K., Cajnko, M. M., Jerala, R., & Benčina, M. (2017) · Nature Communications · doi:10.1038/ncomms15363 · Cited by 55
Self-citationLymphocyte Autophagy in Homeostasis, Activation, and Inflammatory Diseases
Arbogast, F., & Gros, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01801 · Cited by 56
Zeidi, M., Kim, H. J., & Werth, V. P. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.07.041 · Cited by 55
Extracellular Vesicles Derived Human-miRNAs Modulate the Immune System in Type 1 Diabetes
Tesovnik, T., Kovač, J., Pohar, K., Hudoklin, S., Dovč, K., Bratina, N., Podkrajšek, K. T., Debeljak, M., Veranič, P., Bosi, E., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00202 · Cited by 52
Talukdar, A., Ganguly, D., Roy, S., Das, N., & Sarkar, D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00300 · Cited by 55
Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
de Vyver, T. V., Smedt, S. C. D., & Raemdonck, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114041 · Cited by 51
Chandler, L. C., Barnard, A. R., Caddy, S. L., Patrício, M. I., McClements, M. E., Fu, H., Rada, C., MacLaren, R. E., & Xue, K. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.012 · Cited by 50
Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy
Hawtin, S. R., André, C., Zipfel, G., Appenzeller, S., Bannert, B., Baumgartner, L., Beck, D., Betschart, C., Boulay, T., Brunner, H. I., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101036 · Cited by 50
Ballantine, L. E., Midgley, A., Harris, D. A., Richards, E., Burgess, S., & Beresford, M. W. (2015) · Pediatric Rheumatology · doi:10.1186/s12969-015-0007-y · Cited by 50
Janus sword actions of chloroquine and hydroxychloroquine against COVID-19
Chen, X., & Geiger, J. D. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109706 · Cited by 53
Han, J., Li, X., Luo, X., He, J., Huang, X., Zhou, Q., Han, Y., Jie, H., Zhuang, J., Li, Y., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110848 · Cited by 49
“One result suggested that structural modification of DNA by HCQ prevented DNA binding to TLR9 [43] and more evidence is warranted; (3) for in vivo study, it would be better to use mice whose TLR9 knockout was specifically in DCs but not systematically.”
BackgroundChandler, L., Yusuf, I., McClements, M., Barnard, A., MacLaren, R., & Xue, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144972 · Cited by 49
Zhang, R., Kramer, J. S., Smith, J. D., Allen, B. N., Leeper, C. N., Li, X., Morton, L. D., Gallazzi, F., & Ulery, B. D. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0233-6 · Cited by 49
Early Activation of Teleost B Cells in Response to Rhabdovirus Infection
Abós, B., Castro, R., Granja, A. G., Havixbeck, J. J., Barreda, D. R., & Tafalla, C. (2014) · Journal of Virology · doi:10.1128/jvi.03080-14 · Cited by 49
Endosomal Toll‐like receptors in clinically overt and silent autoimmunity
Clancy, R. M., Markham, A. J., & Buyon, J. P. (2015) · Immunological Reviews · doi:10.1111/imr.12383 · Cited by 55
Xourgia, E., & Tektonidou, M. G. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102311 · Cited by 49
TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy
Kim, H., Khanna, V., Kucaba, T. A., Zhang, W., Sehgal, D. N., Ferguson, D. M., Griffith, T. S., & Panyam, J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00271 · Cited by 50
Sustained Activation of Toll-Like Receptor 9 Induces an Invasive Phenotype in Lung Fibroblasts
Kirillov, V., Siler, J. T., Ramadass, M., Ge, L., Davis, J. E., Grant, G. M., Nathan, S. D., Járai, G., & Trujillo, G. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.12.011 · Cited by 52
Extracellular Poly(ADP-Ribose) Is a Pro-inflammatory Signal for Macrophages
Krukenberg, K. A., Kim, S., Tan, E. S., Maliga, Z., & Mitchison, T. J. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.03.007 · Cited by 46
Emerging Therapies in Antiphospholipid Syndrome
ANDRADE, D. C. O. D., & Tektonidou, M. G. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0566-z · Cited by 49
Treatment of systemic lupus erythematosus: new advances in targeted therapy
Lo, M. S., & Tsokos, G. C. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06263.x · Cited by 50
NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load
Pohlkamp, T., Xian, X., Wong, C. H., Durakoglugil, M. S., Werthmann, G. C., Saido, T. C., Evers, B. M., White, C. L., Connor, J., Hammer, R. E., et al. (2021) · eLife · doi:10.7554/elife.72034 · Cited by 46
Colak, E., Leslie, A. J., Zausmer, K., Khatamzas, E., Kubarenko, A. V., Pichulik, T., Klimosch, S. N., Mayer, A., Siggs, O. M., Hector, A., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303058 · Cited by 49
Waele, J. D., Marcq, E., Audenaerde, J. R. M. V., Loenhout, J. V., Deben, C., Zwaenepoel, K., de Kelft, E. V., der Planken, D. V., Menovsky, T., den Bergh, J. M. J. V., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1407899 · Cited by 47
Gardet, A., Pellerin, A., McCarl, C., Diwanji, R., Wang, W., Donaldson, D., Franchimont, N., Werth, V. P., & Rabah, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00275 · Cited by 47
Sieber, J., Daridon, C., Fleischer, S. J., Fleischer, V., Hiepe, F., Alexander, T., Heine, G., Burmester, G. R., Fillatreau, S., & Dörner, T. (2014) · Arthritis Research & Therapy · doi:10.1186/s13075-014-0477-1 · Cited by 48
Targeting TLRs and the inflammasome in systemic sclerosis
Henderson, J., Bhattacharyya, S., Varga, J., & O’Reilly, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.003 · Cited by 46
Dyavar, S. R., Singh, R., Emani, R., Pawar, G. P., Chaudhari, V. D., Podany, A. T., Avedissian, S. N., Fletcher, C. V., & Salunke, D. B. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111794 · Cited by 49
mRNA transfection by a Xentry-protamine cell-penetrating peptide is enhanced by TLR antagonist E6446
Bell, G. D., Yang, Y., Leung, E., & Krissansen, G. W. (2018) · PLOS ONE · doi:10.1371/journal.pone.0201464 · Cited by 43
Mussari, C. P., Dodd, D. S., Sreekantha, R. K., Laxman, P., Wan, H., Posy, S., Critton, D., Ruepp, S. U., Subramanian, M., Watson, A., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00264 · Cited by 44
Hydroxychloroquine for Primary Progressive Multiple Sclerosis
Koch, M. W., Kaur, S., Sage, K., Kim, J., Levesque‐Roy, M., Cerchiaro, G., Yong, V. W., Cutter, G., & Metz, L. M. (2021) · Annals of Neurology · doi:10.1002/ana.26239 · Cited by 47
Robinson, E. S., Alves, P., Bashir, M. M., Zeidi, M., Feng, R., & Werth, V. P. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.05.035 · Cited by 44
Yang, Y.-Z., Chen, P., Liu, L., Cai, Q., Shi, S., Chen, Y., Lv, J., & Zhang, H. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1488-6 · Cited by 43
Richard, S. A., Kampo, S., Hechavarria, M. E., Sackey, M., Buunaaim, A. D. B., Kuugbee, E. D., & Anabah, T. W. (2020) · Journal of Immunology Research · doi:10.1155/2020/4582612 · Cited by 45
Metadata
- Authors
- Kužnik, A., Benčina, M., Švajger, U., Jeras, M., Rozman, B., & Jerala, R.
- Affiliations
- National Institute of Chemistry (SI)
- Blood Transfusion Centre of Slovenia (SI)
- Ljubljana University Medical Centre (SI)
- University of Ljubljana (SI)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04
- Volume
- 186
- Issue
- 8
- Pages
- 4794-4804
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2118400571
- Cited by
- 606
- References
- 40
- Citations by year
- 2026: 21 · 2025: 24 · 2024: 43 · 2023: 30 · 2022: 42 · 2021: 69 · 2020: 89 · 2019: 38 · 2018: 39 · 2017: 38 · 2016: 41 · 2015: 43 · 2014: 32 · 2013: 22 · 2012: 28
- FWCI
- 12.77
- Type
- journal article
- Language
- en
- Open access
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Repository of the University of Ljubljana (University of Ljubljana) (publishedVersion, other-oa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- antimalarial drugs, imidazoquinolines, chloroquine, hydroxychloroquine, quinacrine, TLR8, R848, nucleic acid binding, endosomal acidification, TLR9, TLR3, TLR7/8 agonist, systemic lupus erythematosus, autoimmune disease therapy, propidium iodide, bafilomycin
- MeSH terms
- Animals, Antimalarials, Binding, Competitive, Cell Line, Cells, Cultured, Chloroquine, Culture Media, Humans, Hydrogen-Ion Concentration, Imidazoles, Nucleic Acids, Quinacrine, Quinolines, Endosomes, Transfection, Cytokines, Serum, Toll-Like Receptors, Toll-Like Receptor 3, Toll-Like Receptor 7, Toll-Like Receptor 8, Toll-Like Receptor 9, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.